Experiment Number: **A81105**
Test Type: **Genetic Toxicology - Micronucleus**
Route: **Intraperitoneal Injection**
Species/Strain: **Mouse/B6C3F1**

G04: In Vivo Micronucleus Summary Data
Test Compound: **Catechol**
CAS Number: **120-80-9**

Date Report Requested: **09/21/2018**
Time Report Requested: **05:55:58**

NTP Study Number:	A81105
Study Duration:	72 Hours
Study Methodology:	Slide Scoring
Male Study Result:	Negative

Experiment Number: **A81105**

Test Type: **Genetic Toxicology - Micronucleus**

Route: **Intraperitoneal Injection**

Species/Strain: **Mouse/B6C3F1**

G04: In Vivo Micronucleus Summary Data

Test Compound: **Catechol**

CAS Number: **120-80-9**

Date Report Requested: **09/21/2018**

Time Report Requested: **05:55:58**

Tissue: Bone marrow; Sex: Male; Number of Treatments: 3; Time interval between final treatment and cell sampling: 24 h

		MN PCE/1000		% PCE
Dose (mg/kg)	**N**	**Mean ± SEM**	**p-Value**	**Mean ± SEM**
Vehicle Control[1]	5	2.30 ± 0.20		54.40 ± 2.87
4.69	5	2.90 ± 0.68	0.2024	52.70 ± 1.81
9.38	5	3.10 ± 0.78	0.1378	55.60 ± 3.39
18.75	5	1.50 ± 0.57	0.9030	54.30 ± 1.64
37.5	5	2.20 ± 0.56	0.5593	48.00 ± 3.19
75.0	4	2.13 ± 0.38	0.5978	57.00 ± 1.47
150.0	1	4.00 ± 0.00	< 0.001 *	30.50 ± 0.00
Trend p-Value		0.8290		
Positive Control[2]	5	20.00 ± 0.79	< 0.001 *	52.10 ± 1.85

Trial Summary: Negative

LEGEND

MN = micronucleated, PCE = polychromatic erythrocyte, NCE = normochromatic erythrocyte
CAS Number = Chemical Abstracts Service registry number
N = Number of subjects
Values given as Mean or Mean ± Standard Error Mean
Results were tabulated as the mean of the pooled results from all animals within a treatment group, plus or minus the standard error of the mean
Pairwise comparison to the concurrent control, dosed groups significant at p = 0.025/number of treatment groups; positive control value is significant at p = 0.05
Cochran-Armitage trend test, significant at p = 0.025
* Statistically significant pairwise or trend test
1: Vehicle Control: Phosphate Buffered Saline
2: 15.0 mg/kg Cyclophosphamide

** END OF REPORT **